Analytical Data
-
基因名
IL-36RN
- Application
-
别名
FIL1 deltaIL-1-related protein 3 ;IL-1RP3Interleukin-1 HY1 ;IL-1HY1Interleukin-1 delta ;IL-1 deltaInterleukin-1 family member 5 ;IL-1F5Interleukin-1 receptor antagonist homolog 1 ;IL-1ra homolog 1Interleukin-1-like protein 1 ;IL-1L1
-
种属
Human
-
表达系统
E. coli
-
标签
N- His-SUMO
-
纯度
Greater than 90% as determined by SDS-PAGE. as determined by SDS-PAGE.
-
蛋白编号
Q9UBH0
-
表达区间
1-155aa
-
分子量
33 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-36RN, or Interleukin-36 receptor antagonist, is a protein that plays a crucial role in regulating the immune response, particularly within the IL-36 cytokine family. This family includes IL-36α, IL-36β, and IL-36γ, which are pro-inflammatory cytokines involved in various inflammatory skin diseases, such as psoriasis and dermatitis. IL-36RN functions as a natural inhibitor, counteracting the effects of these pro-inflammatory cytokines by binding to their receptor and preventing their action. The imbalance between IL-36 and IL-36RN has been implicated in the pathogenesis of several autoimmune disorders, making it a critical focus for therapeutic intervention. Research into recombinant forms of IL-36RN aims to explore its potential as a therapeutic agent, providing insights into its structural properties and functional capabilities. Understanding its role in inflammation and immune regulation can lead to novel treatments for chronic inflammatory conditions, underscoring the importance of IL-36RN in both basic immunology and clinical applications. Furthermore, the development of recombinant IL-36RN can facilitate investigations into its mechanisms of action, paving the way for targeted therapies that could alleviate symptoms in affected patients. Such studies are vital, as they not only enhance our understanding of immune regulation but also contribute to the advancement of individualized medicine strategies in treating inflammatory diseases.
